Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2368238
Max Phase: Preclinical
Molecular Formula: C52H76O16
Molecular Weight: 957.16
Molecule Type: Small molecule
Associated Items:
ID: ALA2368238
Max Phase: Preclinical
Molecular Formula: C52H76O16
Molecular Weight: 957.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@@H](OC)[C@@H](O[C@H]4C[C@@H](OC)[C@@H](OC(C)=O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](OC(C)=O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
Standard InChI: InChI=1S/C52H76O16/c1-13-27(2)45-30(5)19-20-51(68-45)25-38-22-37(67-51)18-17-29(4)44(28(3)15-14-16-36-26-59-49-46(62-34(9)53)31(6)21-39(50(55)64-38)52(36,49)56)65-42-24-41(58-12)48(33(8)61-42)66-43-23-40(57-11)47(32(7)60-43)63-35(10)54/h14-17,19-21,27-28,30,32-33,37-49,56H,13,18,22-26H2,1-12H3/b15-14+,29-17+,36-16+/t27-,28-,30-,32-,33-,37+,38-,39-,40+,41+,42-,43-,44-,45+,46+,47-,48-,49+,51+,52+/m0/s1
Standard InChI Key: BJKYXUBVAOZFSM-CQNXJTQUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 957.16 | Molecular Weight (Monoisotopic): 956.5133 | AlogP: 6.52 | #Rotatable Bonds: 10 |
Polar Surface Area: 182.20 | Molecular Species: NEUTRAL | HBA: 16 | HBD: 1 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.60 | CX Basic pKa: | CX LogP: 6.73 | CX LogD: 6.73 |
Aromatic Rings: 0 | Heavy Atoms: 68 | QED Weighted: 0.14 | Np Likeness Score: 2.10 |
1. Mrozik H, Eskola P, Fisher MH, Egerton JR, Cifelli S, Ostlind DA.. (1982) Avermectin acyl derivatives with anthelmintic activity., 25 (6): [PMID:7097720] [10.1021/jm00348a010] |
Source(1):